All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Bookmark this article
The Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked him to revisit his paper on the concept of a bimodal mortality pattern in systemic lupus erythematosus (SLE), first published in 1976,1 and to discuss how trends have evolved over time.
Has the bimodal mortality pattern in SLE evolved in recent years?
Urowitz discusses the inception of the bimodal mortality pattern concept in SLE, where early deaths were linked to active lupus, treatment complications, and infections, whereas later deaths often involved coronary artery disease as a prevalent comorbidity. Then, he emphasizes the importance of recognizing subclinical and preclinical forms of the disease and early intervention. Notably, advancements in managing traditional risk factors, such as smoking; improved medications, for treating conditions like hypertension and diabetes; and improved disease control have resulted in at least a threefold decrease in atherosclerotic disease since the 1970s and 80s.
Editorial theme | LLDAS versus remission as treat-to-target goals
During a meeting of the Lupus Hub Steering Committee, key opinion leaders discussed the topic of LLDAS versus remission as treat-to-target goals.
How might deucravacitinib fit into the treatment pathway for patients with SLE?
During the Lupus Hub Steering Committee meeting, key opinion leaders discussed how deucravacitinib might fit into the treatment pathway for patients with SLE.
Subscribe to get the best content related to lupus delivered to your inbox